title: Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
abstract: OBJECTIVE
  To describe the pharmacokinetics of maraviroc when dosed at 150 or 300 mg once daily with 800/100 mg of darunavir/ritonavir.
  
  
  METHODS
  A retrospective case-note review of HIV-infected adults taking maraviroc was conducted. Patients on a maraviroc-based regimen for a minimum of 5 weeks were grouped as receiving: (i) 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine; (ii) 300 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily; and (iii) 150 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily. C(trough) and C(peak) data were collected at 2, 12 or 24 h post-dose.
  
  
  RESULTS
  Sixty-six patients were included, providing 115 samples. The median (IQR) C(peak) was 378 (350-640) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n=9), 728 (378-935) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n=29) and 364 (104-624) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n=2; P=0.24). The median (IQR) C(trough) was 46 (33-61) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n=12), 70 (49-97) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n=34) and 43 (35-55) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n=17; P=0.001). The maraviroc C(trough) in black patients (n=34) was 61 (45-110) ng/mL and in white patients (n=29) it was 49 (42-70) ng/mL (P=0.04). The C(peak) in black patients (n=20) was 800 (397-1060) ng/mL versus 387 (336-723) ng/mL in white patients (n=20; P=0.02).
  
  
  CONCLUSIONS
  Once daily coadministration of 300 mg of maraviroc with 800/100 mg of darunavir/ritonavir was well tolerated and had favourable pharmacokinetics when compared with 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine. A 24% higher C(trough) and 107% higher C(peak) was seen in black patients compared with white patients.
authors.affiliation: North Middlesex University Hospital, London, UK. chinyere.okoli@nmh.nhs.uk
authors.forename: Chinyere
authors.initials: C
authors.lastname: Okoli
authors.forename: Marco
authors.initials: M
authors.lastname: Siccardi
authors.forename: Sathish
authors.initials: S
authors.lastname: Thomas-William
authors.forename: Ngozi
authors.initials: N
authors.lastname: Dufty
authors.forename: Kirstin
authors.initials: K
authors.lastname: Khonyongwa
authors.forename: Jonathan
authors.initials: J
authors.lastname: Ainsworth
authors.forename: John
authors.initials: J
authors.lastname: Watson
authors.forename: Roseanne
authors.initials: R
authors.lastname: Cook
authors.forename: Kate
authors.initials: K
authors.lastname: Gandhi
authors.forename: Geraldine
authors.initials: G
authors.lastname: Hickinbottom
authors.forename: Andrew
authors.initials: A
authors.lastname: Owen
authors.forename: Stephen
authors.initials: S
authors.lastname: Taylor
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000069454:Darunavir; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D014230:Triazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D013449:Sulfonamides; D014230:Triazoles; D000077592:Maraviroc; D019438:Ritonavir; D000069454:Darunavir